Summary of - Repositioning of antidiabetic drugs for Alzheimer’s disease: possibility of Wnt signaling modulation by targeting LRP6 an in silico based study

Document Type

Article

Abstract

Study Background: The research presented titled “Repositioning of antidiabetic drugs for Alzheimer’s disease: possibility of Wnt signaling modulation by targeting LRP6 an in silico based study” by Suman Manandhar, Keerthi Priya, Chetan H. Mehta, Usha Y. Nayak, Shama Prasada Kabekkodu, K. Sreedhara Ranganath Pai discussed the repositioning of antidiabetic drugs to treat alzheimers disease (AD) targeting LRP6 using insilico tools.

Methodological Approach: The insilico tools including Schrodinger Inc. Linux operating system based 8 GB RAMsystem with intel core 3 processor was used for accessing tools like protein preparation wizard, LigPrep, GLIDE (Grid-based ligand docking with energetic) and Desmond.

Results and Discoveries: From thisin silico study, we can conclude that antidiabetic drugs ofclass a-glucosidase inhibitors, voglibose, miglitol and PPARcagonist: pioglitazone can be beneficial for AD by the mech-anism mediated through Wnt signaling pathway. Both thesedrugs have shown very good binding and interactions withchain A of LRP6, which might be a handful in preventing theinteraction of LRP6 with Wnt antagonist Dkk1. This may helpin activating the canonical Wnt signaling pathway and allevi-ating symptoms of AD.

Publication Year

2021

Recommended Citation

Manandhar S, Priya K, Mehta CH, Nayak UY, Kabekkodu SP, Pai KSR. Repositioning of antidiabetic drugs for Alzheimer's disease: possibility of Wnt signaling modulation by targeting LRP6 an in silico based study. J Biomol Struct Dyn. 2022;40(20):9577-9591.

Publication Date

2021

Link to Full Text

Share

COinS